Management of oligoprogressive and oligopersistent disease in advanced NSCLC Review
| Authors: | Ravella, R.; Feliciano, E. J. G.; Dee, E. C.; Gomez, D. R.; Iyengar, P. |
| Review Title: | Management of oligoprogressive and oligopersistent disease in advanced NSCLC |
| Abstract: | The oligometastatic disease state is defined as an intermediate state between localized cancer and widespread systemic metastases. Oligoprogression is defined as a subgroup in which limited metastatic areas are progressing in the background of oligometastatic or polymeta-static disease, whereas oligopersistent disease refers to an induced state in which formerly polymetastatic disease responds to treatment and decreases to fewer than 5 sites of active disease. With modern improve-ments in systemic therapy for patients with non–small cell lung cancer, including immunotherapies and targeted therapies, there may be a role for local therapy in selected patients with limited metastases—a subset of patients with potentially curable metastatic disease. Improved imaging techniques and advancements in highly conformal delivery of radiotherapy with stereotactic body radiation therapy have increased interest in using ablative radiotherapy or surgery as local consolidation therapy to improve patient outcomes. In this review, we define the oligoprogressive and oligopersistent disease states in patients with non–small cell lung cancer and discuss the evidence for the treatment and management of this patient population, including recent prospective trials and future directions in the selection of patients who will benefit most from local therapy. © 2025, Millennium Medical Publishing, Inc.. All rights reserved. |
| Keywords: | excision; gene mutation; overall survival; systemic therapy; metastasis; progression free survival; carcinoma, non-small-cell lung; lung neoplasms; pathology; protein tyrosine kinase inhibitor; health care quality; lung tumor; immunotherapy; disease progression; radiosurgery; brain metastasis; neoplasm metastasis; disease management; radiofrequency ablation; stereotactic body radiation therapy; disease exacerbation; therapy; non small cell lung cancer; tumor microenvironment; egfr mutation; meta analysis (topic); phase 3 clinical trial (topic); crizotinib; maintenance chemotherapy; humans; human; article; pembrolizumab; atezolizumab; oligometastatic; local consolidative therapy; oligoprogression; nslc; oligopersistent; oligoprogressive; oligopersistent disease |
| Journal Title: | Clinical Advances in Hematology & Oncology |
| Volume: | 23 |
| Issue: | 1 |
| ISSN: | 1543-0790 |
| Publisher: | Millennium Medical Publishing, Inc |
| Date Published: | 2025-01-01 |
| Start Page: | 40 |
| End Page: | 50 |
| Language: | English |
| PUBMED: | 39907576 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Puneeth Iyengar -- Source: Scopus |
Citation Impact
Related MSK Work